BETA
Atlanta-based manufacturer of portable X-ray systems for point-of-care orthopedic imaging.
OXOS Medical develops portable X-ray equipment. The company traces its founding to 2016 as Micro C, LLC.; its current MC2 system follows the earlier Micro C.
MC2 is offered in Clinic, LE, Go and Lab configurations. The company reports U.S. availability and provides direct sales contact options; these statements do not establish customer numbers or deployment scale.
Intel Capital announced a $23 million Series A co-led with Parkway Venture Capital in April 2023, reporting $45 million raised at that time. Those historical figures do not establish current financing or financial health.
MC2 has FDA 510(k) decisions K241567 and K252068 and is commercially available in the United States. The later labeling includes specified adult and pediatric imaging and excludes surgery and home/residential use. Earlier Micro C decisions are recorded as a separate platform lineage. [5][6][18][17][14][1]
The matched FDA history contains 1 distinct recall event: 1 open, 0 terminated. Z-2857-2026 (2026-06-11; open, classified): Due to a defective circuit board that overheats [11]
Latest recorded source review: 2026-10-20.
Scope: selected product families.
One product family, offered in several configurations.
Portable X-ray platform for point-of-care orthopedic imaging. Clinic, LE, Go and Lab configurations offer different combinations of imaging modes and accessories; permitted clinical uses depend on the configuration and FDA labeling.
FDA-cleared · U.S.In March 2026, OXOS announced pediatric imaging availability for MC2. This is an expansion of the marketed platform, rather than evidence of a separate pending application or a future launch date. [16]
FDA records a firm-initiated recall, Z-2857-2026. The FDA posting followed on August 3, 2026; affected scope and current status are in the regulatory entry. [22]
OXOS announced pediatric imaging availability for MC2. This is a company announcement date, separate from the FDA decision date. [16]
FDA recorded a second MC2 substantial equivalence determination, K252068. [21]
FDA recorded a substantial equivalence determination under K241567. [20]
Intel Capital reported a round co-led with Parkway Venture Capital. The announcement put cumulative funding at $45 million at that time. [24]
OXOS reports that its predecessor, Micro C, LLC., was founded in 2016. [15]
Accessed 10/29/2026